Boston - Model BOS172738 - ATP-Competitive RET (Rearranged during Transfection) Kinase Inhibitor
From Oncology
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas.
-
Most popular related searches
Asset Overview
- BOS172738 demonstrates potent preclinical activity in RET-driven tumors derived from patient-derived xenografts.
- BOS172738 is highly potent with selectivity to multiple genetically-altered forms of RET kinase, including resistance mutations such as V804M.
Customer reviews
No reviews were found for Boston - Model BOS172738 - ATP-Competitive RET (Rearranged during Transfection) Kinase Inhibitor. Be the first to review!